Needle-Free Drug Injection Systems: Global Strategic Business Report

Global Needle-Free Drug Injection Systems Market to Reach $29.9 Billion by 2030

The global market for Needle-Free Drug Injection Systems estimated at US$12.6 Billion in the year 2022, is projected to reach a revised size of US$29.9 Billion by 2030, growing at a CAGR of 11.4% over the analysis period 2022-2030. Jet Injectors, one of the segments analyzed in the report, is projected to record 11.5% CAGR and reach US$9.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Novel Needle-Free segment is readjusted to a revised 10.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $3.4 Billion, While China is Forecast to Grow at 15.6% CAGR

The Needle-Free Drug Injection Systems market in the U.S. is estimated at US$3.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$6.7 Billion by the year 2030 trailing a CAGR of 15.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 9.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Select Competitors (Total 52 Featured) -

• AKRA Dermojet
• Crossject SA
• D`Antonio Consultants International, Inc.
• Medical International Technologies, Inc.
• National Medical Products, Inc.
• PharmaJet
• Zogenix, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year